In this deep-dive episode, we unpack Ketamine and Esketamine in Psychiatric Practice: What PMHNPs Need to Know in 2026. Ketamine and esketamine are reshaping treatment-resistant depression care, with expanded indications and new delivery models emerging in 2026. PMHNPs must understand the differences between IV ketamine, intranasal esketamine (Spravato), and oral ketamine, including REMS requirements, monitoring protocols, and scope of practice considerations. Read the full post: https://psychnpfellowship.com/ketamine-esketamine-psychiatric-practice-pmhnp-2026/